Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC

SAN DIEGO September 14, 2020Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that Ciara Kennedy, Ph.D, president and chief executive officer, has been invited to present at A Too Quiet Pandemic – Fungal Disease webinar, presented by Maxim Group LLC and M-Vest, on Thursday September 17th, 2020. Dr. Kennedy will participate in a panel discussion led by Dr. Jason McCarthy, Maxim’s senior managing director of Biotechnology Equity Research, along with other important voices in the healthcare industry.

Webinar Details:

     Panel Session Title: A Too Quiet Pandemic – Fungal Disease 

     Date and Time: Thursday, September 17, 11:00 a.m. ET (8:00 a.m. PT)

Register to attend via link

About Amplyx Pharmaceuticals
Amplyx Pharmaceuticals is developing innovative therapies for patients with compromised immune systems, including cancer and transplant patients, and the critically ill. The company’s two lead products are fosmanogepix (APX001), a first-in-class antifungal, for the treatment of life-threatening fungal infections caused by pathogens such as CandidaAspergillus and rare molds, and MAU868, a novel human monoclonal antibody that potently neutralizes the BK virus, which can cause significant morbidity and mortality in transplant patients. For more information, please visit

Heidi Chokeir, Ph.D.
Managing Director
Canale Communications
(619) 203-5391